Houston-based Welch Foundation has awarded almost $28 million in chemical research grants throughout Texas this year. Photo via Getty Images

Chemical researchers at seven institutions in the Houston area are receiving nearly $12.9 million grants from the Houston-based Welch Foundation.

In the Houston area, 43 grants are going to seven institutions:

  • Baylor College of Medicine
  • Rice University
  • Texas A&M University
  • Texas A&M University Health Science Center
  • University of Houston
  • University of Texas Health Science Center at Houston
  • University of Texas Medical Branch in Galveston

The Welch Foundation is awarding almost $28 million in chemical research grants throughout Texas this year. The money will be allocated over a three-year period.

“Today, chemical research is more important than ever for improving the human condition and for meeting the global challenges that threaten our collective future,” says Adam Kuspa, president of the Welch Foundation. “Basic research in chemistry and related fields provides the foundation for groundbreaking scientific discoveries that can help solve current problems and sustain progress.”

Two of the 2022 grant recipients cited by the foundation are:

  • Josephine Chu Ferreon, assistant professor of pharmacology and chemical Biology at the Baylor College of Medicine. She plans to use her Welch grant to conduct research on intrinsically disordered proteins (IDPs) and their potential applications in biotech and nanomedicine. IDPs, known as “dancing proteins,” do not form uniquely defined 3D structures. Because of the structural flexibility, IDPs can pair with ordered proteins to perform functions that structured proteins can’t do on their own.
  • David Powers, assistant professor of chemistry at Texas A&M. He leads a research group focused on the relationship between organic and inorganic chemistry. Members of the group are trying to develop new methods for the sustainable synthesis of functional molecules.

Since its establishment in 1954, the Welch Foundation has contributed more than $1.1 billion to the advancement of chemistry in Texas. Last year, the organization granted $23 million in funds.

The Welch Foundation has announced millions in Texas research funding. Photo via Getty Images

Houston-based research grant program doles out $23M to Texas scientists

funds for the future

One of the nation's largest private funders for health care research has announced $23 million in fresh funds — and about a third of that is going into the hands of Houstonians.

The Welch Foundation, based in Houston, announced its 2021 research grant funding last week. Over the next three years, the funds will be be distributed in $7,520,000 payouts annually across the state of Texas. Since its founding in 1954, the foundation has doled out almost $1.1 billion to the advancement of chemistry.

"Ongoing basic chemical research is critical and provides the building blocks to help solve current and future problems," says Adam Kuspa, president of The Welch Foundation, in a news release. "Funding from The Welch Foundation is a valuable resource to Texas institutions. It helps set our state's researchers apart from others and we look forward to seeing what invaluable scientific contributions come from this year's grant recipients."

The universities in the Houston area that received a cut of this chunk of funding include Rice University, Texas A&M University, University of Houston, and Baylor College of Medicine for a total of $8,400,000 across 35 grants.

One of the Houston-area researchers who received funding is Leila Romero, assistant professor and CPRIT Scholar in Cancer Research at Baylor University's Department of Chemistry and Biochemistry. Romero and her team is exploring modes of asymmetric catalysis and to study how these new processes work. According to the release, the funding will also support the training of young graduate students at the institution who are on track to become future innovators in chemical synthesis.

Other Texas institutions in other major cities also received funding:

  • The Dallas/Fort Worth area received funding for 42 grants, totaling $10,080,000. The University of Texas Southwestern Medical Center, The University of Texas at Dallas, University of North Texas, Baylor University, Southern Methodist University, and Texas Christian University were the recipient institutions.
  • In Austin, the University of Texas Received funding for 11 grants, totaling $2,640,000.
  • The University of Texas at San Antonio and Trinity University received the three grants — totaling $720,000 — that went to the San Antonio area.
  • In West Texas, The University of Texas at El Paso received funding for 1 grant, totaling $240,000.
  • Texas Tech University received funding for two grants, totaling $480,000

Last year, the Welch Foundation announced a $100 million gift to Rice University to establish The Welch Institute. The institute will foster the study of matter, the design and discovery of new materials, and nanotechnology, and it will be led by an independent board of directors and scientific advisory board.

Kuspa, who's led the foundation since September 2019, joined the Houston Innovators Podcast last December to discuss the new institute and the importance of supporting researchers in Texas.


This week's innovators to know roundup includes Heath Butler and Samantha Lewis of Mercury Fund and Adam Kuspa of the Welch Foundation. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's Monday roundup of Houston innovators, I'm introducing you to three innovators across the city — each in their own ways financially support the region's top innovators.


Heath Butler and Samantha Lewis of Mercury Fund

Heath Butler has been promoted to managing director of Mercury Fund, and Samantha Lewis joins the firm as principal. Photos courtesy

Houston-based Mercury Fund, which focuses on early-stage startups located in central United States, announced the promotion of Heath Butler to managing director from network partner. Additionally, Samantha Lewis — formerly investment director at Houston-based Goose Capital — is joining the fund as principal.

"Over the past few years, we've continued to build our investment team with top talent from our ecosystem," says Blair Garrou, co-founder and managing director of Mercury, in a news release.

"The promotion of Heath and the addition of Samantha will further Mercury's early-stage venture leadership in Middle America, and is illustrative of Mercury's deep commitment to diversity as a core value driver," continues Garrou. Click here to read more.

Adam Kuspa of The Welch Foundation

Adam Kuspa of The Welch Foundation joins the Houston Innovators Podcast to discuss the COVID-19 vaccine, materials science, and more. Photo courtesy of The Welch Foundation

It's been an interesting year for Adam Kuspa and the Welch Foundation as — just like any other organization — the pandemic has caused various disruptions for Kuspa and his team. At the same time, COVID-19 has forced an unprecedented public-private response from the medical community, the government, and more.

"I'm very proud of the scientific enterprise in this country and around the world — they way it's been supported, developed, and maintained over the years — to allow for something like this be even contemplated," Kuspa says on this week's episode of the Houston Innovators Podcast.

Over the last 40 to 50 years, researchers in the fields immunology, vaccine research, protein biochemistry, and more, have seen increased support, Kuspa says, and that's what made a difference in the pandemic and allowed for a vaccine to emerge so quickly. Click here to read more and to listen to the episode.

Adam Kuspa of The Welch Foundation joins the Houston Innovators Podcast to discuss the COVID-19 vaccine, materials science, and more. Photo courtesy of The Welch Foundation

Houston nonprofit leader on the importance of supporting research — from COVID-19 to materials science

HOUSTON INNOVATORS PODCAST EPISODE 62

The Welch Foundation, a Houston-based nonprofit that supports researchers across the state, has identified a need to dedicate resources toward a specific field of study that affects everyone on a daily basis — and has done so for years: materials science.

"There's a reason that paleontologists and historians named the ages of human society after materials — the Bronze Age, the Stone Age, the Iron Age," Adam Kuspa, president of the Welch Foundation, says on this week's episode of the Houston Innovator's podcast.

"You don't think about it, but it's because those materials transformed the way humans could interact with other humans and their environment," he continues. "Now, we're in this age of advanced materials. Every way a human interacts with their environment involves a material."

Despite this revolutionary moment the field is in, materials science still tends to be a relatively underfunded sector of research with a lot of potential, Kuspa says. That's among the reasons that the organization announced its plan to create the Welch Institute at Rice University focused on materials science. The announcement included a $100 million gift to the university, and the institute's physical location is currently under construction.

Aside from this recent announcement, it's been an interesting year for the Welch Foundation as — just like any other organization — the pandemic has caused various disruptions for Kuspa and his team. At the same time, COVID-19 has forced an unprecedented public-private response from the medical community, the government, and more.

"I'm very proud of the scientific enterprise in this country and around the world — they way it's been supported, developed, and maintained over the years — to allow for something like this be even contemplated," Kuspa says.

Over the last 40 to 50 years, researchers in the fields immunology, vaccine research, protein biochemistry, and more, have seen increased support, Kuspa says, and that's what made a difference in the pandemic and allowed for a vaccine to emerge so quickly.

"All of these things that have been going on in the background that the public has been blissfully unaware of — the thousands of researchers that have been doing this work over decades — has allowed for the concept of a COVID-19 vaccine to be brought forward in a short time," Kuspa says. "From identifying the source of a pandemic illness in December 2019 to be vaccinating against that illness within 12 months is astonishing."

Kuspa shares more about the new institute and his thoughts on how both COVID-19 and its vaccine will affect modern medicine in the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


This week's Houston innovators to know include Adam Kuspa of The Welch Foundation, Amanda Ducach of Social Mama, and Jay Rogers of IBC Bank. Photos courtesy

3 Houston innovators to know this week

Who's who

During this ongoing pandemic, Houston innovators are coming up with solutions and relief across every industry.

This week's three Houston innovators to know include a researcher who is helping fund scientists across the state, a Houston momtrepreneur looking out for the women wearing several hats at home, and a banker who wants to help you keep your financial information secure online.

Adam Kuspa, president of The Welch Foundation

The Welch Foundation, led by Adam Kuspa, funds basic research across the state of Texas — research that's important both in and out of pandemic. Photo courtesy of The Welch Foundation

Adam Kuspa observes the impressive work researchers across the state are doing across the chemical and biomedical disciplines as president of Houston-based Welch Foundation, but his job looks a little differently now. As COVID-19 has taken center stage in the world, people are desperate for a cure and vaccine.

However, as the race to find these solutions, Kuspa — along with other researchers and scientists — is watching carefully to see how the disease and its to-be solutions will affect research and medical innovations as a whole.

"What people forget in the rush to get a drug out is that you could also make matters worse," he says. "Drugs don't automatically cure or are neutral. They can also do harm. So, you want to be careful not to make the situation worse." Click here to read more.

Amanda Ducach, founder and CEO of SocialMama

Amanda Ducach quickly upgraded her app, SocialMama, to help increase virtual access to health care professionals for moms stuck inside during the COVID-19 crisis. Photo courtesy of SocialMama

With much of society working from home, a huge burden has been placed on parents who are juggling their careers and homeschooling their children for the rest of the academic year. In many situations, the bulk of this responsibility has weighed heavy on moms, and a Houston momtrepreneur knew how to help them out.

Amanda Ducach, founder and CEO of SocialMama, created her app to link up moms for friendship and mentorship, and she was planning on expanding the app to add in experts and professionals into the mix this summer. However, when COVID-19 hit, she realized this was something moms needed ASAP.

"We learned quickly that moms' behaviors were drastically changing throughout this process of the pandemic, but also that over a million babies were going to be born in isolation," Ducach says on this week's episode of the Houston Innovators Podcast. "That really changes the walk around maternal health." Click here to read more and stream the podcast.

Jay Rogers, chairman and CEO of IBC Bank

You are more vulnerable to financial cyber threats in a crisis. Here are some tips for staying safe. Photo courtesy of IBC Bank

You know what you might not have thought of during these unprecedented times? Cybersecurity. Lucky for you, Jay Rogers of IBC Bank has. He shared his tips for keeping your financial information safe online in a guest column for InnovationMap.

"This is a time of great need," he writes. "Unfortunately, it is also a time of great opportunity for criminals. As Houstonians respond, as they always do, be sure to protect yourself while you are helping our community." Click here to read the article.

The Welch Foundation, led by Adam Kuspa, funds basic research across the state of Texas — research that's important both in and out of pandemic. Photo courtesy of The Welch Foundation

Houston-based nonprofit leader believes COVID-19 will have long-term effects on important research

Q&A

It's Adam Kuspa's job to provide support to Texas researchers as they attempt to create innovative chemical and biochemical solutions for the betterment of mankind.

Formerly the dean of research at Baylor College of Medicine, Kuspa now serves as president of Houston-based Welch Foundation, which has, over the past several decades, provided nearly $800 million in research funding across the state.

Kuspa, through the organization, regularly sees revolutionary chemical discoveries being innovated in Texas across the 60 institutions he works with. It's usually an exciting job.

"I've spent my career, at least the last 15 years or so, helping other people do their research — before as being in research at Baylor College of Medicine," Kuspa tells InnovationMap. "I really enjoy enabling very, very smart people to do creative, innovative science. It's a lot of fun."

However, as the race to find a cure and vaccine to COVID-19 heats up, Kuspa — along with other researchers and scientists — is watching carefully to see how the disease and its to-be solutions will affect research and medical innovations as a whole.

"What people forget in the rush to get a drug out is that you could also make matters worse," he says. "Drugs don't automatically cure or are neutral. They can also do harm. So, you want to be careful not to make the situation worse."

Kuspa sat down with InnovationMap to discuss The Welch Foundation's mission, as well as some of his observations on potential cures for COVID-19 and what concerns he has.

InnovationMap: Tell me about the Welch Foundation and what role it plays in Texas?

Adam Kuspa: For over 65 years, the Welch Foundation has pursued its mandate based on Robert Welch's thought from the 1950s that chemistry was very important to the improvement of mankind. And so, our mandate is to fund foundational research in chemistry in the state of Texas, working through academic institutions throughout the state. We've done that consistently for the past 65 years through several programs.

IM: What type of research does the foundation fund usually?

AK: The research grant program gives grants to individual investigators, and we're doing about 300 to 400 continuously throughout the state of Texas. There's also block grants to departments to encourage students to become involved in chemical research. And we have other programs such as our endowed chair programs. We've given out about 40 endowed professorships, which support specific professors at individual institutions and their chemical research.

I should point out that chemistry research from our perspective is broadly defined and includes biochemistry of material sciences, et cetera. Currently our grant portfolio consists of 50 percent biomedical research grants, which is relevant to current current situation with COVID-19.

IM: How do you connect to Texas research institutions usually?

AK: We have fairly typical calls for applications for research grants or departmental grants and for our two award programs: the Welch Award in Chemistry, which is given out every year in Houston, and the Norman Hackerman Award, for junior faculty researchers in state of Texas.

A lot of the work is going out in the community to visit with the researchers and our academic institution partners. That, of course, has been curtailed, but typically we would visit any one of the 60 or so institutions that we support on a cycle of several years. So, that involves going to the chemistry departments, speaking with faculty, hearing how the research is going, and getting feedback on how our programs can be improved.

We also have an annual research conference, which unfortunately has been canceled this year, but typically draws 200 to 800 participants from around the state with speakers coming in around the world. This year, it was meant to be on neuroscience. Last October, the conference concerned genome editing. So, it's quite exciting, and the conferences, which are always held in Houston, are generally very well attended. They are a good way to start to interact with the scientific community in general.

IM: What has been the organization’s focus during the pandemic?

AK: We are obligated to fund foundational research in chemistry and allied fields, like biochemistry. So, we're not at liberty to fund development of therapies, for instance. However, I would say an interesting way to look at this is that we hear a lot about a search for a therapeutic for COVID-19 and, obviously, a search for vaccine — these begin with research.

Since it normally takes 15 to 18 years to bring a drug to market from first principles of how you're going to interrupt the human biology to effecting a cure, you're hearing a lot about testing existing drugs or their potential therapeutic effect on COVID-19. The reason we're able to do that is because we have a lot of drugs that are in the process of being developed and drugs that are already approved for human use. It's a lot more efficient to try to look at the potential utility of those already human-approved drugs and their potential effect on viral replication.

So, we sort of view our role as the Welch Foundation as funding that foundational research — either in drug development from a chemical perspective or in funding foundational work in how viruses attack the human body in the first place. And, although we give out grants for basic research, our investigators are pretty industrious. When there's a situation like the COVID-19 pandemic, a number of them turned their attention towards the problem at hand.

Another way that we've supported the general availability of potential therapeutics is that we've made a large grant to The Center for Drug Discovery at the Baylor College of Medicine directed by Martin Matzuck. And the reason we were interested in helping to get that center started is because they had an idea to make a drug discovery and development much more efficient and cost effective. That promotes a general capability of Houston and Texas in terms of being able to bring about potential therapeutics to wide range of diseases, but potentially for COVID-19 specifically.

IM: What’s the usual process of getting a drug from research stage to use?

AK: There are four phases of testing. Phase one is for safety, phase two is for dosing and potential efficacy, and phase three is for broad range of efficacy — large numbers of patients and trials that take hundreds of millions of dollars to perform. Approval by FDA occurs after phase three, but then there's actually a phase four study, which is following the drug for potential adverse effects once it is in common use by the public.

You may remember there's a drug called Vioxx — it's a very good pain reliever. But, in the phase four study, after millions of prescriptions were written already, it was found to cause rare heart problems and heart attacks. People were dying spontaneously, and it was hard to pin that specifically on Vioxx, but you can do it statistically from the phase four trial after the drug was introduced.

So, the reason you hear about hydroxychloroquine as a treatment for COVID-19 is because you sort of get the short circuit and skip those phases and jump right to phase four studies where you know it's basically safe and you roughly know how to dose. But what you don't though is how that approved drug can be used for particular indications like COVID-19 and how safe it is.

You can't actually jump the normal 18-year process, and with existing drugs you're still only at year 15, where you're got another few years to figure out how to actually use them in the context of the COVID-19.

IM: Scientists and researchers are working on solutions, but what are the challenges they are facing?

AK: That's a great question. Given that we have so many research grants around the state, we get input literally on an hourly basis from our grantees on the status of their research because of the interruption. And the short story is that all research has been shut down in the state of Texas except for research directly related to coronavirus.

Large biomedical research centers, which have hundreds of millions of dollars a year in external research funding going to cure a broad range of disease have shut all of their labs down, except for the few labs that are working directly on COVID-19. That includes vaccine discovery and production.

A lot of work has been wasted because often biological experiments take weeks and months of progression, and if can't complete the final steps, you'll have to start over.

IM: Do you think this will have a long-term effect on research?

AK: I think so. Science, as it turns out, is a very creative, human-interactive activity. It's actually much more social than people realize. It's not the individual scientist working at the lab bench only. It's a lot of travel, seminars given by out-of-town speakers, scientific conferences, gatherings of hundreds of people.

The annual neuroscience conference attracts 40,000 people every year from all over the world — and that's not happening. As far as we can tell, all scientific conferences have been canceled for the rest of 2020. When I talked to my colleagues and professors around the country, every out of town seminar has been canceled. So, the exchange of information that's been so vital to stimulate creativity and collaboration between laboratories isn't happening, and there are new venues have to be found to do that online. But there is going to be a limitation. I think people are adapting, and we'll just have to see how it unfolds.

The published literature is one to one-and-a-half years behind what's actually happening in the laboratory. So, the way people learn about what's going on — the failed experiments, the things you're trying out, the exciting new ideas — is generally through face-to-face interactions. And that happens by scientists traveling between universities and at conferences in the hallways between the formal sessions. That aspect is absolutely vital to the progress of science.

IM: What is something you want people to know about the basic research that the Welch Foundation is funding?

We need consistency and support for basic research because, during a pandemic, we want to have a cure, but we don't think about the hundreds of thousands of scientists across the country who are struggling to get funding for the basic research when there's not a pandemic.

Additionally, this basic research is also the engine for industry — particularly the biotech industry in Houston, and folks have been really working hard to try to ensure that there's an ecosystem for new companies to be formed out of Houston. I think part of the reason why we might survive this current oil glut as opposed to the mid 1980s is that the Houston economy is diversified with — not just with the port and NASA — but with biomedical research and patient care. In Houston, health care is the largest employer — it's larger than oil and gas. That kind of diversification is good for the economy and good for the innovation environment that people in Houston have tried really to make happen for the last 10 years or so.

------

This conversation has been edited for brevity and clarity.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Med tech firm expands footprint, Houston innovator assumes new role, and more local innovation news

short stories

Houston's innovation ecosystem has had some big news this month, from new job titles for Houston innovators to expanding office space.

In this roundup of Houston startup and innovation news, a Houston organization expands its footprint in the TMC, Rice University opens applications for a cleantech accelerator, and more.

Organization expands footprint in Houston

Proxima CRO has announced its expansion within TMCi. Photo via Twitter

Proxima Clinical Research, a contract research organization headquartered in Houston, announced that it is expanding its office space in the Texas Medical Center Innovation Factory.

"Texas Medical Center is synonymous with innovation, and the TMC Innovation space has proven an ideal location for our CRO. It's an important part of our origin story and a big part of our success," says Kevin Coker, CEO and co-founder of Proxima CRO, in a news release.

The expansion will include around 7,500-square feet of additional office space.

"The resources found across TMC's campuses allow for companies such as Proxima Clinical Research to achieve clinical and business milestones that will continue to shape the future of life sciences both regionally and globally. We are excited for Proxima to expand their footprint at TMC Innovation Factory as they further services for their MedTech customers," says Tom Luby, director of TMC Innovation, in the release.

$20M grant fuels hardtech program's expansion

Activate is planting its roots in Houston with a plan to have its first set of fellows next year. Photo via Activate.org

A hardtech-focused nonprofit officially announced its Houston expansion this week. Activate, which InnovationMap reported was setting up its fifth program here last month, received a $20M commitment by the National Science Foundation to fuel its entrance into the Bayou City.

“Houston’s diversity offers great promise in expanding access for the next generation of science entrepreneurs and as a center of innovation for advanced energy," says NSF SBIR/STTR program director Ben Schrag in a news release.

The organization was founded in Berkeley, California, in 2015 to bridge the gap between the federal and public sectors to deploy capital and resources into the innovators creating transformative products. The nonprofit expanded its programs to Boston and New York before launching a virtual fellowship program — Activate Anywhere, which is for scientists 50 or more miles outside one of the three hubs.

“We are delighted to be opening our newest Activate community in Houston,” says Activate Anywhere managing director Hannah Murnen, speaking at the annual Advanced Research Projects Agency-Energy Innovation Summit. “Houston is a city where innovation thrives, with an abundance of talent, capital, and infrastructure—the perfect setting for the Activate Fellowship.”

Activate is still looking its Houston’s first managing director is actively underway and will select fellows for Activate Houston in 2024.

TMC names new entrepreneur in residence

Zaffer Syed has assumed a new role at TMC. Photo via TMC.org

Houston health tech innovator has announced that he has joined the Texas Medical Center's Innovation Factory as entrepreneur in residence for medtech. Zaffer Syed assumed the new role this month, according to his LinkedIn, and he's been an adviser for the organization since 2017.

Syed has held a few leadership roles at Saranas Inc., a medical device company founded in Houston to detect internal bleeding following medical procedures. He now serves as adviser for the company.

"As CEO of Saranas, he led the recapitalization of the company that led to the FDA De Novo classification and commercial launch of a novel real-time internal bleed monitoring system for endovascular procedures," reads the TMC website. "Zaffer oversaw clinical development, regulatory affairs and strategic marketing at OrthoAccel Technologies, a private dental device startup focused on accelerating tooth movement in patients undergoing orthodontic treatment.

"Prior to working in startup ventures, Zaffer spent the first 13 years of his career in various operational roles at St. Jude Medical and Boston Scientific to support the development and commercialization of Class III implantable devices for cardiovascular and neuromodulation applications."

TMC is currently looking for an entrepreneur in residence for its TMCi Accelerator for Cancer Therapeutics program.

Applications open for clean energy startup program

Calling all clean energy startups. Photo courtesy of The Ion

The Clean Energy Accelerator, an energy transition accelerator housed at the Ion and run by the Rice Alliance for Technology and Entrepreneurship, has opened applications for Class 3. The deadline to apply is April 14.

The accelerator, which helps early-stage ventures reach technical and commercial milestones through hybrid programming and mentorship, will host its Class 3 cohort from July 25 to Sept. 22.

“Accelerating the transition to a net-zero future is a key goal at Rice University. Through accelerating the commercial potential of our own research as well as supporting the further adoption of global technologies right here in Houston, the Rice Alliance Clean Energy Accelerator is proof of that commitment,” says Paul Cherukuri, vice president of innovation at Rice, in a news release. “The Rice Alliance has all the critical components early-stage energy ventures need for success: a corporate innovation network, energy investor network, access to mentors and a well-developed curriculum. This accelerator program is a unique opportunity for energy startups to successfully launch and build their ventures and get access to the Houston energy ecosystem.”

According to Rice, the 29 alumni companies from Class 1 and 2 have gone on to secure grants, partnerships, and investments, including more than $75 million in funding. Companies can apply here, learn more about the accelerator here or attend the virtual information session April 3 by registering here.

Houston-based real estate giant rolls out sustainability-focused business unit

seeing green

Houston-based real estate investor, developer, and manager Hines is stepping up its commitment to sustainability.

The company just formed a business unit, EXP by Hines, that is aimed at addressing “the disruptive changes in the built environment.”

EXP by Hines comprises two parts: Global ESG and the Global Venture Lab. Doug Holte, who was a senior partner at Hines from 1987 to 2009, has been hired as CEO of EXP.

“EXP by Hines is an engine of growth using the most innovative ideas in capital, culture, and environmental stewardship to connect every stakeholder in the built environment and create healthy, activated communities,” Holte says in a news release. “EXP is looking beyond the boundaries of real estate to solve complex problems while creating long-term value.”

Peter Epping, who joined Hines in 2001, is the company’s global head of ESG (environmental, social, and governance). A 2022 survey by professional services firm Deloitte found that ESG continues to gain ground in the corporate world. Business executives questioned for the survey believe ESG strategies will:

  • Strengthen stakeholder trust
  • Elevate brand reputation
  • Boost employee retention
  • Improve ROI
  • Reduce risk

Kathryn Scheckel, who joined Hines in 2019, leads the company’s new Global Venture Lab, which is tasked with identifying and accelerating ventures, partnerships and investments. The lab includes a startup incubator and a VC arm.

According to the news release, priorities of the Global Venture Lab include innovations in the use of physical space, development of ESG solutions, and creation of “revolutionary built-world technologies.”

The efforts being spearheaded by Holte, Epping, and Scheckel are geared in part toward Hines achieving net zero carbon by 2040 in its nearly 231 million-square-foot global portfolio without buying carbon credits.